Upper limit re-evaluation of drugs in the negotiation stage

with the NHIS

Initiate prior consultation

The re-evaluation of the drug cap amount according to the standard requirement has now moved to the negotiation stage with the NHIS.

 

Pharmaceutical companies that submitted their primary drugs to the HIRA by last February will proceed with prior consultation with the NHIS in March.

 

After that, the main negotiations will be completed and the final drug price adjustment results will be announced in July.

 

The NHIS announced on the 15th that it will hold prior consultations with pharmaceutical companies from this month in accordance with the re-evaluation of the standard requirements for the maximum amount of drugs.

 

Accordingly, the NHIS plans to hold a briefing on the reevaluation negotiations on the 27th.

 

An official from the corporation said, "We recently shared matters related to negotiations on standard requirements through a meeting with pharmaceutical organizations." About 15,000 drugs will be targeted for the first round, and prior consultations will be held until May.

 

During the preliminary consultation period, the items to be negotiated will be checked and an agreement will be sought, so it is expected that the agreement will be concluded during the main negotiations in June.

 

Based on this, the contents of the final drug price adjustment will be announced in July after going through the review committee in June.

 

Negotiations are underway for the second target drug.

 

The secondary target drugs are about 5,000, and if data are submitted to the HIRA by July, negotiations will proceed with the NHIS again.

 

Negotiations will be conducted by the NHIS Pharmaceutical Control Office's Generic Management Division.

 

An official from the generic management department explained, "Based on our experience over the past two years, we are thoroughly preparing to complete the negotiations within the deadline." The re-evaluation of the upper limit amount is being carried out by maintaining or lowering the upper limit amount depending on whether the company's own BA test and DMF registration criteria are met.

 

If both of the BA and DMF requirements are met, the upper limit is maintained, and if one is met, the price is reduced to 85% of the adjusted standard price, and if both are not met, the price is reduced to 72.25%.